HK Stock Market Move | BEIGENE (06160) rose by more than 6% with a victory in a US patent dispute. The company achieved strong growth in performance last year.

BEIGENE (06160) rose by over 6%, as of the time of writing, it rose by 6.04% to HK$158, with a turnover of HK$547 million. On the news front, in the morning of April 30th, BEIGENE announced that the United States Patent and Trademark Office made a final written decision declaring the invalidity of all rights of Pharmacyclics' '803 patent challenged by the company in the '803 patent authorization reexamination process. Pharmacyclics may appeal the USPTO's final written decision. The company stated that its original research drug, BTK inhibitor Bai Yuz, is involved in the patent infringement accusation, and the company will vigorously defend against such allegations. BeiGene achieved a total revenue of approximately US$3.81 billion in 2024, a year-on-year increase of approximately 55%; product revenue increased by approximately 72.6% to approximately US$3.8 billion. Gross profit was approximately US$3.216 billion, a year-on-year increase of 54.71%. The company's annual performance showed strong growth, demonstrating its strength as a global leader in cancer treatment. This is due to the continued success of Bai Yuz and one of the richest solid tumor pipelines developed by the company in the field of oncology, with multiple projects expected to have data readouts by 2025.